Search
Search Results
##search.searchResults.foundPlural##
-
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1425HTML: 484PDF: 845 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4112PDF: 1169HTML: 2004Fig.1: 223Fig. 2: 114Table 1: 209Table2: 228Table 3: 206 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
1003PDF: 542HTML: 731 -
ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
4135PDF: 1272HTML: 1967Table 1: 209 -
SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM
2304PDF: 920HTML: 2104 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
2535PDF: 629Suppl. Files: 292HTML: 179 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2085PDF: 855HTML: 262 -
The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study
2443PDF: 957HTML: 330 -
EPIDEMIOLOGY OF MALARIA IN ENDEMIC AREAS
5395PDF: 2684HTML: 49611 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3253PDF: 795HTML: 2976Figure 1a and 1b: 159Figure 2: 165Figure 3: 185Figure 4: 169Figure 5: 170Tables 1-5: 158 -
PROPHYLAXIS OF MALARIA
3059PDF: 1054HTML: 17854Figures SChwartz: 177 -
MANAGEMENT OF PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS
834PDF: 546HTML: 4026 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2014PDF: 887HTML: 704 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4033PDF: 1070HTML: 3607Untitled: 180Cneo. Fig.1: 117Untitled: 109Untitled: 136Untitled: 137 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2706PDF: 960HTML: 561 -
ON THE VERSATILITY OF VON WILLEBRAND FACTOR
2870PDF: 1155HTML: 11229 -
DYNAMIC MONITORING OF ADAMTS 13 ACTIVITY FOR DIFFERENTIAL DIAGNOSIS ACROSS THE SPECTRUM OF SEPSIS ASSOCIATED WITH THROMBOTIC MICROANGIOPATIES Adamts 13 and Sepsis Associated with Thrombotic Thrombocytopenic Purpura
768PDF: 667HTML: 94 -
-
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4217PDF: 1965HTML: 5346Table 1: 219 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1286PDF: 1087HTML: 219 -
-
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7741PDF: 2455HTML: 1745Table 1.: 226Table 2.: 239Table 3.: 221Table 4.: 215 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1337PDF: 1030HTML: 127 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2301PDF: 902HTML: 2009Fig 1 Rossi: 203 -
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
4371PDF: 1400HTML: 2063 -
LIVER IRON CONTENT IN INDIVIDUALS WITH LIVER IRON CONTENT IN INDIVIDUALS WITH Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS.: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS. Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA
198PDF: 125Suppl. Files: 19HTML: 6 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2365PDF: 1673HTML: 303 -
EARLY PREDICTIVE VALUE OF PERIPHERAL INFLAMMATORY INDEX COMBINED WITH HIGH-SENSITIVITY TROPONIN T FOR SEPSIS-INDUCED CARDIOMYOPATHY Inflammatory and Troponon T in cardiomyopaty from Sepsis
296PDF: 308HTML: 35 -
POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia
536PDF: 259HTML: 46







